Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices

Charles D. Fraser, Xun Zhou, J. Trent Magruder, Alejandro Suarez-Pierre, Cecillia Lui, Joshua C. Grimm, Robert Higgins, Ahmet Kilic

Research output: Contribution to journalArticle

Abstract

Objective: Sensitization has been associated with worse outcomes following heart transplantation (HTx). The use of ventricular assist devices (VAD) is a risk factor for the development of sensitization. We investigated the impact of left ventricular assist devices (LVAD) and sensitization in HTx recipients. Methods: We queried the UNOS database for all heart transplants performed from January 2000 through December 2016. Patients were considered highly sensitized and included if panel-reactive antibody (PRA) activity was 25% or higher. Patients were separated by pretransplant LVAD utilization and subgroup analysis was performed by device type (HeartMate II or HeartWare). Outcomes included Kaplan-Meier survival and episodes of rejection within 1 year of HTx. Results: Of 18 009 recipients, 2434 (14%) were highly sensitized. 1055 (43.3%) were bridged with a VAD. In multivariate analysis, LVAD use did not impact 1-year (hazards ratio [HR], 1.30; P = 0.052) or 5-year survival (HR, 1.18; P = 0.112) in highly sensitized recipients. Furthermore, episodes of rejection were not affected by LVAD status (P = 0.765). Of the 1055 sensitized LVAD-bridged transplant recipients, 624 (59%) were implanted with a HeartMate II and 99 (9.4%) were bridged with a HeartWare device. In multivariate analysis, no differences were observed in 1-year survival (HR, 0.86; P = 0.664), 5-year survival (HR, 1.35; P = 0.209), or episodes of rejection (P = 0.497). Conclusions: The use of ventricular assist devices did not impact survival or rejection within 1 year of HTx in highly sensitized patients. Highly sensitized recipients have similar outcomes regardless of prior LVAD support or type of LVAD used as a bridge to transplantation.

Original languageEnglish (US)
Pages (from-to)474-481
Number of pages8
JournalJournal of Cardiac Surgery
Volume34
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Heart-Assist Devices
Heart Transplantation
Survival
Multivariate Analysis
Equipment and Supplies
Transplantation
Databases
Transplants

Keywords

  • heart transplantation
  • panel-reactive antibody
  • sensitization

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices. / Fraser, Charles D.; Zhou, Xun; Magruder, J. Trent; Suarez-Pierre, Alejandro; Lui, Cecillia; Grimm, Joshua C.; Higgins, Robert; Kilic, Ahmet.

In: Journal of Cardiac Surgery, Vol. 34, No. 6, 01.06.2019, p. 474-481.

Research output: Contribution to journalArticle

Fraser, Charles D. ; Zhou, Xun ; Magruder, J. Trent ; Suarez-Pierre, Alejandro ; Lui, Cecillia ; Grimm, Joshua C. ; Higgins, Robert ; Kilic, Ahmet. / Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices. In: Journal of Cardiac Surgery. 2019 ; Vol. 34, No. 6. pp. 474-481.
@article{69bff6def42340cead695b33e8ce20c9,
title = "Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices",
abstract = "Objective: Sensitization has been associated with worse outcomes following heart transplantation (HTx). The use of ventricular assist devices (VAD) is a risk factor for the development of sensitization. We investigated the impact of left ventricular assist devices (LVAD) and sensitization in HTx recipients. Methods: We queried the UNOS database for all heart transplants performed from January 2000 through December 2016. Patients were considered highly sensitized and included if panel-reactive antibody (PRA) activity was 25{\%} or higher. Patients were separated by pretransplant LVAD utilization and subgroup analysis was performed by device type (HeartMate II or HeartWare). Outcomes included Kaplan-Meier survival and episodes of rejection within 1 year of HTx. Results: Of 18 009 recipients, 2434 (14{\%}) were highly sensitized. 1055 (43.3{\%}) were bridged with a VAD. In multivariate analysis, LVAD use did not impact 1-year (hazards ratio [HR], 1.30; P = 0.052) or 5-year survival (HR, 1.18; P = 0.112) in highly sensitized recipients. Furthermore, episodes of rejection were not affected by LVAD status (P = 0.765). Of the 1055 sensitized LVAD-bridged transplant recipients, 624 (59{\%}) were implanted with a HeartMate II and 99 (9.4{\%}) were bridged with a HeartWare device. In multivariate analysis, no differences were observed in 1-year survival (HR, 0.86; P = 0.664), 5-year survival (HR, 1.35; P = 0.209), or episodes of rejection (P = 0.497). Conclusions: The use of ventricular assist devices did not impact survival or rejection within 1 year of HTx in highly sensitized patients. Highly sensitized recipients have similar outcomes regardless of prior LVAD support or type of LVAD used as a bridge to transplantation.",
keywords = "heart transplantation, panel-reactive antibody, sensitization",
author = "Fraser, {Charles D.} and Xun Zhou and Magruder, {J. Trent} and Alejandro Suarez-Pierre and Cecillia Lui and Grimm, {Joshua C.} and Robert Higgins and Ahmet Kilic",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/jocs.14066",
language = "English (US)",
volume = "34",
pages = "474--481",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices

AU - Fraser, Charles D.

AU - Zhou, Xun

AU - Magruder, J. Trent

AU - Suarez-Pierre, Alejandro

AU - Lui, Cecillia

AU - Grimm, Joshua C.

AU - Higgins, Robert

AU - Kilic, Ahmet

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Objective: Sensitization has been associated with worse outcomes following heart transplantation (HTx). The use of ventricular assist devices (VAD) is a risk factor for the development of sensitization. We investigated the impact of left ventricular assist devices (LVAD) and sensitization in HTx recipients. Methods: We queried the UNOS database for all heart transplants performed from January 2000 through December 2016. Patients were considered highly sensitized and included if panel-reactive antibody (PRA) activity was 25% or higher. Patients were separated by pretransplant LVAD utilization and subgroup analysis was performed by device type (HeartMate II or HeartWare). Outcomes included Kaplan-Meier survival and episodes of rejection within 1 year of HTx. Results: Of 18 009 recipients, 2434 (14%) were highly sensitized. 1055 (43.3%) were bridged with a VAD. In multivariate analysis, LVAD use did not impact 1-year (hazards ratio [HR], 1.30; P = 0.052) or 5-year survival (HR, 1.18; P = 0.112) in highly sensitized recipients. Furthermore, episodes of rejection were not affected by LVAD status (P = 0.765). Of the 1055 sensitized LVAD-bridged transplant recipients, 624 (59%) were implanted with a HeartMate II and 99 (9.4%) were bridged with a HeartWare device. In multivariate analysis, no differences were observed in 1-year survival (HR, 0.86; P = 0.664), 5-year survival (HR, 1.35; P = 0.209), or episodes of rejection (P = 0.497). Conclusions: The use of ventricular assist devices did not impact survival or rejection within 1 year of HTx in highly sensitized patients. Highly sensitized recipients have similar outcomes regardless of prior LVAD support or type of LVAD used as a bridge to transplantation.

AB - Objective: Sensitization has been associated with worse outcomes following heart transplantation (HTx). The use of ventricular assist devices (VAD) is a risk factor for the development of sensitization. We investigated the impact of left ventricular assist devices (LVAD) and sensitization in HTx recipients. Methods: We queried the UNOS database for all heart transplants performed from January 2000 through December 2016. Patients were considered highly sensitized and included if panel-reactive antibody (PRA) activity was 25% or higher. Patients were separated by pretransplant LVAD utilization and subgroup analysis was performed by device type (HeartMate II or HeartWare). Outcomes included Kaplan-Meier survival and episodes of rejection within 1 year of HTx. Results: Of 18 009 recipients, 2434 (14%) were highly sensitized. 1055 (43.3%) were bridged with a VAD. In multivariate analysis, LVAD use did not impact 1-year (hazards ratio [HR], 1.30; P = 0.052) or 5-year survival (HR, 1.18; P = 0.112) in highly sensitized recipients. Furthermore, episodes of rejection were not affected by LVAD status (P = 0.765). Of the 1055 sensitized LVAD-bridged transplant recipients, 624 (59%) were implanted with a HeartMate II and 99 (9.4%) were bridged with a HeartWare device. In multivariate analysis, no differences were observed in 1-year survival (HR, 0.86; P = 0.664), 5-year survival (HR, 1.35; P = 0.209), or episodes of rejection (P = 0.497). Conclusions: The use of ventricular assist devices did not impact survival or rejection within 1 year of HTx in highly sensitized patients. Highly sensitized recipients have similar outcomes regardless of prior LVAD support or type of LVAD used as a bridge to transplantation.

KW - heart transplantation

KW - panel-reactive antibody

KW - sensitization

UR - http://www.scopus.com/inward/record.url?scp=85066864013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066864013&partnerID=8YFLogxK

U2 - 10.1111/jocs.14066

DO - 10.1111/jocs.14066

M3 - Article

C2 - 31045281

AN - SCOPUS:85066864013

VL - 34

SP - 474

EP - 481

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 6

ER -